M
Martin Babor
Researcher at Institute of Chemical Technology in Prague
Publications - 18
Citations - 260
Martin Babor is an academic researcher from Institute of Chemical Technology in Prague. The author has contributed to research in topics: Chemistry & Engineering. The author has an hindex of 4, co-authored 10 publications receiving 162 citations.
Papers
More filters
Journal ArticleDOI
Electron diffraction determines molecular absolute configuration in a pharmaceutical nanocrystal.
TL;DR: This work shows that dynamical diffraction effects are strong enough to permit unambiguous determination of the absolute structure of material composed of light scatterers and presents a complete structure analysis of a pharmaceutical cocrystal of sofosbuvir and l-proline.
Journal ArticleDOI
CrystalCMP: an easy‐to‐use tool for fast comparison of molecular packing
TL;DR: In this article, a new approach is introduced for the comparison of molecular packing and the identification of identical crystal structure motifs, using a simple formula involving the distances between molecular centres and the relative orientations of molecular entities inside a finite molecular cluster.
Journal ArticleDOI
First Crystal Structures of Pharmaceutical Ibrutinib: Systematic Solvate Screening and Characterization
TL;DR: In this article, the authors performed a tailor-made systematic solvate screening and tested several solution and slurry based methods in the solvates screening for their suitability and success rate.
Journal ArticleDOI
Formation of the first non-isostructural cocrystal of apremilast explained
Jan Jirát,Vít Zvoníček,Martin Babor,Luděk Ridvan,Eliška Skořepová,Michal Dušek,Miroslav Soos +6 more
TL;DR: Search for new multicomponent solid forms has become a key step in the pharmaceutical drug development and Apremilast, a poorly soluble API used for the treatment of psoriatic arthritis, was used as a template for this study.
Journal ArticleDOI
Complex methodology for rational design of Apremilast-benzoic acid co-crystallization process
TL;DR: A new co-crystal of pharmaceutical active ingredient Apremilast with benzoic acid significantly improves key properties like the dissolution and stability of an otherwise poorly soluble Ap Remilast and is proposed to be combined into a single methodology based on solubility data.